MedicaidPrior AuthMedium impact
Liposomal doxorubicin (Revised)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Dec 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has updated prior authorization criteria for liposomal doxorubicin (Doxil, Lipodox) covering six oncology conditions. The policy establishes specific diagnosis and treatment combination requirements that must be met for approval.
Action Required
By December 1, 2025: Oncology billing teams must ensure prior authorization is obtained for all liposomal doxorubicin products (Doxil, Lipodox) for Louisiana Medicaid patients. Verify patient diagnosis matches one of six covered conditions (Non-Hodgkin's lymphoma, Breast Cancer, Hodgkin Lymphoma, Kaposi's Sarcoma, Multiple Myeloma, Ovarian Cancer) and meets specific treatment criteria before administration. Claims will be denied without proper prior authorization.